First People's Hospital Reports Findings in Liver Function (Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome).

A recent study conducted at the First People's Hospital in Wuhan, China, explored the use of arsphenamine-based peptides in the treatment of infant hepatitis syndrome (IHS) in children under one year old. The study compared the effects of this treatment with a control group that received reduced glutathione. The results showed that the treatment group had significantly lower levels of serum bilirubin and alanine transferase, as well as higher levels of CD4, CD3, and CD4/CD8, indicating improved liver function and immune function. The study concluded that the combination of arsphenamine and reduced glutathione was more effective in treating IHS. This research has been peer-reviewed and published in the World Journal of Gastrointestinal Surgery. [Extracted from the article]